Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.

Archives of neurology - 1 Apr 2005

Zappia Mario, Annesi Grazia, Nicoletti Giuseppe, Arabia Gennarina, Annesi Ferdinanda, Messina Demetrio, Pugliese Pierfrancesco, Spadafora Patrizia, Tarantino Patrizia, Carrideo Sara, Civitelli Donatella, De Marco Elvira V, Cirò-Candiano Innocenza C, Gambardella Antonio, Quattrone Aldo

Abstract excerpt

BACKGROUND: Several factors, both clinical and genetic, may account for the risk of developing levodopa-induced peak-dose dyskinesias (PDD) in patients with Parkinson disease, but it is unclear how these factors interact for modulating the individual susceptibility for PDD. OBJECTIVE: To examine clinical and genetic risk factors for determining individual susceptibility of PDD in patients with Parkinson disease....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiparkinson Agents
Share to DNA Repeat Expansion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dyskinesia, Drug-Induced

Share to Levodopa

Share to Multivariate Analysis

Share to Parkinson Disease

Share to Receptors, Dopamine D2

Share to Sex Characteristics

Source

Identifiers

PMID: 15824260
DOI: 10.1001/archneur.62.4.601

Genes

DRD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.PMID 15824260Read ↗

Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.Semantic proximity Read ↗

Parkinson’s Disease Pharmacogenomics: New Findings and PerspectivesSemantic proximity Read ↗

Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.Semantic proximity Read ↗

Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease.Semantic proximity Read ↗

Sex differences in Parkinson’s disease: Features on clinical symptoms, treatment outcome, sexual hormones and geneticsSemantic proximity Read ↗

The role of genetic factors in the occurrence of levodopa-induced motor complications in Parkinson's disease.Semantic proximity Read ↗

Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson’s DiseaseSemantic proximity Read ↗

Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.Semantic proximity Read ↗

Pharmacogenetics and levodopa induced motor complicationsSemantic proximity Read ↗

Genetic variants of vitamin D metabolism-related DHCR7/NADSYN1 locus and CYP2R1 gene are associated with clinical features of Parkinson's disease.Semantic proximity Read ↗

Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.Semantic proximity Read ↗

Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.